Covington Reps Forest Labs In $1.2B Clinical Data Deal

Law360, New York (February 22, 2011, 2:12 PM EST) -- Forest Laboratories Inc. announced Tuesday that it would purchase Clinical Data Inc. for $1.2 billion, aiming to add Clinical Data's newly approved drug Viibryd to its portfolio of blockbuster antidepressants.

New York-based Forest, which makes antidepressants Lexapro and Celexa, is proposing to pay Clinical Data $30 in cash per share to buy up all outstanding shares of its common stock, along with contingent consideration of up to an additional $6 per share that will be paid when and if Viibryd's net U.S. sales meet or exceed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.